Results 111 to 120 of about 117,898 (292)

Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia [PDF]

open access: bronze, 2010
Giuseppe Saglio   +15 more
openalex   +1 more source

Diagnosing Systemic Mastocytosis: State of the Art

open access: yesInternational Journal of Laboratory Hematology, EarlyView.
ABSTRACT With the advent of effective multikinase and selective tyrosine kinase inhibitors in systemic mastocytosis, diagnosing this rare disease has been critical to improving patient morbidity and mortality. This state‐of‐the‐art review interprets the international diagnostic criteria, including differences between the WHO 5th edition classification ...
Anton Rets, Tracy I. George
wiley   +1 more source

Ruthenium Complexes in Protein Science: Heading a New Generation of Therapeutic and Analytical Tools

open access: yesAngewandte Chemie, Volume 138, Issue 4, 22 January 2026.
This review presents the latest advances in the development of ruthenium complexes within the field of protein science, highlighting their potential applications in biomedical and bioanalytical fields. Abstract Ruthenium complexes are distinguished by their versatile coordination chemistry, redox behaviors and photochemical properties. In recent years,
Liyan Zhang, Yun Chen, Sylvestre Bonnet
wiley   +2 more sources

Precision medicine in cutaneous melanoma—A comprehensive review

open access: yesJournal of the European Academy of Dermatology and Venereology, EarlyView.
Precision medicine tailors treatment to each patient, beginning with detailed diagnostics. In melanoma, it has advanced considerably: Some methods are in practice and guidelines, while others are commercially available but not routine. This review highlights current and emerging approaches, including molecular profiling, imaging, biomarkers and AI ...
Markus Reitmajer, Lukas Flatz
wiley   +1 more source

Structural Basis for the Regulation of PPARγ Activity by Imatinib

open access: yesMolecules, 2019
Imatinib is an effective anticancer drug for the treatment of leukemia. Interestingly, when an FDA-approved drug library was tested for agents that block peroxisome proliferator-activated receptor γ (PPARγ) phosphorylation at Ser245 to evaluate
Jun Young Jang   +2 more
doaj   +1 more source

Dermatofibrosarcoma Protuberans in Children: Favorable Outcomes Using Wide Local Excision

open access: yesPediatric Dermatology, EarlyView.
ABSTRACT Background Dermatofibrosarcoma protuberans (DFSP) is a rare and locally aggressive cutaneous sarcoma. Surgical excision remains first‐line therapy, including for pediatric patients. However, given the rarity of DFSP, specific treatment recommendations for children have not been well defined. To inform pediatric‐specific management, we analyzed
Jawad Aqeel   +5 more
wiley   +1 more source

Pathogenic Role of mTORC1 and mTORC2 in Pulmonary Hypertension. [PDF]

open access: yes, 2018
Concentric lung vascular wall thickening due to enhanced proliferation of pulmonary arterial smooth muscle cells is an important pathological cause for the elevated pulmonary vascular resistance reported in patients with pulmonary arterial hypertension ...
Ayon, Ramon J   +18 more
core   +1 more source

Philadelphia chromosome‐positive acute lymphoblastic leukaemia in children and adolescents: A changing treatment landscape and a methodological challenge

open access: yes
British Journal of Haematology, EarlyView.
Adriana Balduzzi   +19 more
wiley   +1 more source

Five Cases of Hepatic Mesenchymal Tumors Diagnosed by Endoscopic Ultrasound‐Guided Tissue Acquisition

open access: yesDEN Open, Volume 6, Issue 1, April 2026.
ABSTRACT Percutaneous biopsy remains the gold standard for diagnosing focal liver lesions; however, endoscopic ultrasound‐guided tissue acquisition (EUS‐TA) has recently emerged as a promising alternative. Although its diagnostic performance is favorable, most available evidence has focused on epithelial tumors, and reports on mesenchymal tumors are ...
Yuichi Takano   +9 more
wiley   +1 more source

Discontinuation of imatinib in Japanese patients with chronic myeloid leukemia

open access: yesHaematologica, 2012
It was recently recognized that some chronic myeloid leukemia patients with a complete molecular response could sustain that response after discontinuation of imatinib.
Naoto Takahashi   +16 more
doaj   +1 more source

Home - About - Disclaimer - Privacy